Neratinib, a tyrosine kinase inhibitor approved by the food and drug administration (FDA) for the treatment of human epidermal growth factor receptor 2(HER2)-positive breast cancer, has been demonstrated to promote ferroptosis and inhibit brain metastases [174]. The gene discussed is ERBB2; the disease is breast carcinoma.